Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/26/26
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/26/26
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/19/26
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewsWire • 02/18/26
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)GlobeNewsWire • 02/09/26
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyGlobeNewsWire • 01/26/26
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/13/26
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney DiseaseGlobeNewsWire • 12/01/25
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease TranscriptSeeking Alpha • 11/10/25
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung DiseaseGlobeNewsWire • 11/10/25
MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with DiabetesGlobeNewsWire • 11/06/25